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Depression and anxiety play an important role in decreasing quality of life worldwide. Since tryptophan is a serotonin precursor and low levels of serotonin seems to be related to depression, the effect of oral tryptophan has been investigated for possible potentiation of the action of antidepressant drugs. We investigated the effects of chronically administered tryptophan (50 mg/kg/day, p.o.) with or without concomitant fluoxetine (10 mg/kg/day, s.c.) on adult rats regarding depression-related and anxiety-like behaviors. Tryptophan levels in cerebrospinal fluid (CSF) were measured 4 h after a single administration of daily dosages of chronic treatments. We found that tryptophan increased depressive-related behavior, but did not alter anxiety-like behavior. However, fluoxetine decreased depression-related behavior and was anxiogenic. Tryptophan with concomitant fluoxetine did not alter anxiety-like behavior. Moreover, our data suggests that the antidepressant effect of fluoxetine was not enhanced by concomitant administration of tryptophan, which could be associated with increased levels of tryptophan in CSF. Further investigations are needed to elucidate the related mechanisms.
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Serotonin (5-HT) has been shown to play a crucial role not only in physiological processes, but in the mood and behavior too [15] . Symptoms of depression, panic, aggression and suicidality have been associated with low levels of 5-HT and suicide behavior secondary to depressive disorder seem to be associated with elevated expression of neuronal tryptophan hydroxylase 2 (TPH2) as well as changes in brain serotonin turnover [1] . Due to these facts, the study of the psychopathology of mood disorders has focused on serotonergic system as target for new therapies. The biosynthesis of the monoamine 5-HT starts with the essential amino acid tryptophan, which is metabolized to 5-hydroxytryptophan (5-HTP) by tryptophan hydroxylase (TPH, being the TPH2 the central isoform, specifically expressed in the brain and the TPH1 the peripheral isoform [30] ) in an initial, ratelimiting step; 5-HTP is then further decarboxylated to 5-HT by aromatic amino acid decarboxylase. Despite the initial and rateAbbreviations: CSF, cerebrospinal fluid; EPM, elevated plus-maze; FST, forced swimming test; p.o., per oral; SSRI, selective serotonin reuptake inhibitor; 5-HT, serotonin; s.c., subcutaneously; TPH, tryptophan hydroxylase; 5-HTP, 5-hydroxytryptophan; 5HIAA, 5-hydroxyindole-acetic acid.
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limiting step of the serotonin synthesis being the hydroxylation by TPH2 in the brain, the serotonin level is a product of both synthesis and degradation. It has been proved low dietary tryptophan seems to have an anxiogenic and depressant effect on rat behavior [33] , while acute depletion in adult rats seems to enhance the emotional responsiveness to stress situations [29] . Oral administration of tryptophan has been shown to increase serotonin synthesis and metabolism in different brain regions in rats [11, 14] and improve cognitive functions [14] . In this regard, tryptophan has potential therapeutic effect in an attempt to increase levels of serotonin and its precursors in the brain of subject affected by anxiety or mood disorders.
Fluoxetine, has been applied in the treatment of depression among human with different ages and, more recently, this drug was also recommended for the treatment of anxiety [18] . The antidepressant effect of fluoxetine in rats submitted to the forced swimming test (FST) has ever been established [16, 20] .
Few data exist about chronic effects of tryptophan and interaction with selective serotonin reuptake inhibitors (SSRIs), hence we investigate the effects of a 48-days treatment of oral tryptophan with or without concomitant fluoxetine in adult rats. Animal behavior during the FST and the elevated plus-maze (EPM) was analyzed in order to assess whether the administration of tryptophan as a dietary supplement may be useful in enhancing the fluoxetine effects regarding depression-related and/or anxiety-like behaviors.
Sixty-seven male Wistar rats (60 days old, weighting 230-280 g), which were obtained from our own breeding colony (University of Passo Fundo), were used. Animals were kept in temperature-regulated room (22 ± 1 • C), on a 12 h light/ 12 h dark cycle, four per cage, with food and water ad libitum and air relative humidity was kept at 55 ± 5%. Our institutional protocols for experiments with animals ("Guidelines for Animal Care"), designed to avoid suffering and limit the number of animals used, were followed throughout. The methodology of this study was in strict accordance with the ethical principles in animal experiments of the Brazilian College of Animal Experimentation and with the National Institutes of Health Guide for Care and Use of Laboratory Animals.
Animals used to behavioral tests: Thirty-three male Wistar rats were treated once a day with saline (NaCl 0.9%, 5 mL/kg p.o.) or l-tryptophan (50 mg/kg, 5 mL/kg p.o., Sigma, USA) [14] with concomitant administration of saline (NaCl 0.9%, 1 mL/kg s.c.) or fluoxetine (10 mg/kg, 1 mL/kg s.c., Sigma, USA) [16] for 48 days, performing the following groups: control group -saline (s.c. and p.o.); l-tryptophan group -saline s.c. and l-tryptophan p.o.; fluoxetine group -saline p.o. and fluoxetine s.c.; experimental groupl-tryptophan p.o. and fluoxetine s.c. In this study, fluoxetine was used as a negative control for depression-related behavior.
Animals used to CSF tryptophan measurement: Thirty-six male Wistar rats were treated with a single administration of daily dosages of chronic treatments described above.
The behavioral tests were performed 4 h after the daily administration of drugs and the animals had a habituation period of 2 h at the local test.
The modified FST [5, 6] was conducted at 42 days of treatment. The rats were placed individually in a tank (73 cm diameter, 56 cm height, filled for a depth of 30 cm with water and kept at 25 • C). The rats were removed after 15 min, dried, and returned to their cage. Twenty-four hours after, the rats were replaced in the swim tank (under the same conditions) for 5 min, and the analysis of time spent in immobility, swimming or climbing behaviors was made, quantified with aid of digital chronometers.
The EPM test was made 4 days after the forced-swimming test. The maze was made of plexiglas, having 2 closed arms (50 cm length, 10 cm width) with transparent walls, and 2 open arms of equal length and width, forming a square cross with a 10 cm × 10 cm center piece. The distance from the floor was of 43 cm. The environment was silent and dimly lit (no light directly focused the apparatus). Animals were placed individually in the center of the maze, in junction between open and closed arms, facing one of the open arms, and observed for 5 min, evaluating the time spent in open, closed arms and center of the maze and open, and closed entries [21] .
Animals used for sampling CSF were treated as specified above, with a single administration at the same time of day that chronic treatment was made. Four hours after administration, rats were anesthetized with ketamine (80 mg/kg, Vetbrands, Brazil) and xylazine (10 mg/kg, Coopers Brasil Ltda., Brazil) i.p., placed in a stereotaxic apparatus, and CSF samples (40-60 L per rat) were drawn by direct puncture of the cisterna magna with an insulin syringe (27 gauge × 1/2 in. length) [4] . In order to obtain cellfree supernatants, all samples were centrifuged at 10,000 × g in an eppendorf centrifuge during 5 min and samples stored (−70 • C) until tryptophan quantification by high-performance liquid chromatography (HPLC).
HPLC was performed with CSF cell-free supernatant aliquots to quantify tryptophan levels [13] . Briefly, samples were derivatized with o-phthalaldehyde and separation was carried out with a reverse phase column (Supelcosil LC-18, 250 mm × 4.6 mm, Supelco) in a Shimadzu Instruments liquid chromatograph (50 L loop valve injection). The mobile phase flowed at a rate of 1.4 mL/min and column temperature was 24 • C. Buffer composition is A: 0.04 mol/L sodium dihydrogen phosphate monohydrate buffer, pH 5.5, containing 20% of methanol; B: 0.01 mol/L sodium dihydrogen phosphate monohydrate buffer, pH 5.5, containing 80% of methanol. The gradient profile was modified according to the content of buffer B in the mobile phase: 0% at 0.00 min, 25% at 13.75 min, 100% at 15.00-20.00 min, 0% at 20.01-25.00 min. Absorbance was read at 360 nm and 455 nm, excitation and emission respectively, in a Shimadzu fluorescence detector. Samples of 50 L were used and concentration was expressed in M.
Data were expressed as mean ± standard error mean (S.E.M.) and analyzed by two-way ANOVA followed by simple main effects test if interaction was positive. Independent samples T-test was used for comparing experimental × control groups for parameters without significant interaction between treatments. For all analyses, p < 0.05 was considered significant. Two-way ANOVA was conducted for examining the effect of fluoxetine and tryptophan on parameters of FST and EPM. There was no significant interaction between the treatments in any of the experimental parameters. Independent samples T-test did not found difference between experimental and control group for any behavioral parameter, except climbing at FST (T = 3.119, p = 0.007).
Immobility: Isolated effects were found for fluoxetine [F(1,29) = 4.942, p = 0.034] and tryptophan [F(1,29) = 15.723, p < 0.001], reducing and increasing the time spent in immobility behavior, respectively (Fig. 1A) .
Swimming: Isolated effects were found for fluoxetine [F(1,29) = 6.113, p = 0.02], which increased the time of swimming behavior. In addition, tryptophan showed a tendency to decrease time of swimming [F(1,29) = 4.012, p = 0.055] (Fig. 1B) .
Climbing: Tryptophan showed an isolated effect diminishing the time of climbing behavior [F(1,29) = 9.185, p = 0.005]. Fluoxetine did not have effect at this parameter (Fig. 1C) .
Open arms: Fluoxetine decreased the time spent in open arms [F(1,29) = 20.941, p < 0.001]. Tryptophan had no effect for this parameter ( Fig. 2A) .
Closed arms: Fluoxetine increased the time spent in closed arms [F(1,29) = 12.754, p = 0.001]. Tryptophan showed no effect for this parameter (Fig. 2B) .
Center area: Fluoxetine increased time spent in the center area [F(1,29) = 9.587, p = 0.004]. Tryptophan showed no effect for this parameter (Fig. 2C) .
Ratio of entries (open arms vs. total): Fluoxetine had an isolated effect which decreased the ratio of entries [F(1,29) = 10.722, p < 0.01]. Tryptophan did not affect the ratio of entries (Fig. 3) . Two-way ANOVA was conducted for examining the effect of acute (a single dose) tryptophan and fluoxetine administration on CSF tryptophan levels. There was a significant interaction between the effects of these compounds (Fig. 4) .
We investigated the hypothesis of potentiation of the effect of fluoxetine by tryptophan on depression-related and anxiety-like behavior. It was hypothesized that administration of tryptophan would affect mood and behavior due to an effect over serotoninergic system -resulting from a possible increase in brain 5-HT levels.
According to our data, oral tryptophan administration increased depression-related behavior assessed by the FST, showing increased immobility time, decreased climbing and showing a ten- dency to decrease swimming behavior. Fluoxetine alone decreased depression-related behavior, since it decreased the immobility behavior and increased the swimming time (Fig. 1) . In the EPM, tryptophan did not alter the anxiety-like behavior, while that fluoxetine demonstrated an anxiogenic effect (Figs. 2 and 3) .
Our data suggests that the concomitant administration of tryptophan and fluoxetine does not improve the effect of fluoxetine decreasing depressive-related behavior. There was a trend of interaction between tryptophan and fluoxetine in immobility behavior (Fig. 1A) , which might suggest some loss of fluoxetine effect and could be associated with increased levels of tryptophan in CSF (Fig. 4) . We also observed that concomitant administration did not alter anxiety-like behaviors (Figs. 2 and 3) .
The results found with fluoxetine decreasing depression-related behavior and its anxiogenic effect, are in accordance with previously studies, even with different routes of administration [20, 26, 31] . It has been purposed that existence of some controversial effects of fluoxetine on anxiety-like behavior are due to different posologies [7, 9] . However, studies regarding acute fluoxetine administration with different routes and doses (between 10 and 30 mg/kg) found, in the majority of cases, an increase in extracellular brain 5-HT levels [2] and it has been shown that subcutaneous administration of fluoxetine increases extracellular levels of 5-HT in brain similarly to intraperitoneal administration [8, 22] .
It is known that the onset of the therapeutic effects of all SSRIs requires drug administration for several weeks or even months [19] although many studies investigate the effects of fluoxetine treatment and its mechanism of action under acute treatments [8, 12, 22] .
Controversial data have emerged demonstrating an inability of tryptophan intervention in slowing depression in humans [24] . Studies with animal model demonstrated that the combination of tryptophan with fluoxetine, zimelidine, clomipramine, and amitryptyline has only occasionally achieved any potentiation or acceleration of the clinical effect [32] . However, pretreatment with tryptophan conferred citalopram response in the FST in two otherwise citalopram-insensitive mouse strains [3] and 5-HTP administration after fluoxetine treatment increased 5-HT levels [8] .
Studies with tryptophan restriction showed increased in immobility behavior of rats under FST. This depressive behavior could be related to decrease of serotoninergic activity [16, 33] . However, our data suggests that oral tryptophan seems not to have effect in a context without dietary restrictions or depletion of 5-HT in the brain.
In experimental group, the increased availability of tryptophan to the brain would not be necessary due to the action of fluoxetine. Moreover, it is known that excessive tryptophan may lead to deletery effects on brain, such as convulsions and apoptosis [27] and oral administration of tryptophan produces a consequent increase in tryptophan in plasma and blood [10, 11] , thus this amino acid may be directed to other metabolic pathways [23] . About 1% of dietary tryptophan is converted to 5-HT [23] and oral administration of tryptophan in humans causes an increase of 5-HT and 5-hydroxyindole-acetic acid (5HIAA), especially when there is depletion of 5-HT [10] .
Evidence show that the FST generated decreased in integrated optical density of TPH-positive regions [31] and this effect could explain the lower level of brain tryptophan. Although, we found increase levels of tryptophan in CSF with acute and concomitant administration of fluoxetine and tryptophan, which may indicate an acute and transient effect of these two treatments. This neurochemical effect in CSF tryptophan concentrations was not found in tryptophan and fluoxetine administration singly (Fig. 4) . Previous studies reported a significant increase in the brain 5-HT synthesis [17, 28] and increased expression of the enzyme THP2 [25] after acute administration of this SSRI.
These findings suggest that a chronic treatment, using tryptophan as a nutritional supplement, as well as the performance of behavioral tests, may alter the expression or activity of the enzyme 5-HTP, an essential step for the synthesis of 5-HT. It was not possible to verify a benefic effect tryptophan alone or even of concomitant administration of fluoxetine and tryptophan in our study.
The possibility that other mechanisms may be operating simultaneously for the effect shown in the experimental group, as a larger increase in 5-HT enzymatic degradation by monoamine oxidase cannot be ruled out. In this context, further studies are needed for elucidate the mechanisms by which oral tryptophan in combination or not with fluoxetine induced such effects.
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